Abstract | IMPORTANCE: OBJECTIVE: DESIGN, SETTING, AND PARTICIPANTS: INTERVENTIONS: MAIN OUTCOME MEASURES: Number of infectious exacerbations during 12 months of treatment. Secondary end points included lung function, sputum bacteriology, inflammatory markers, adverse effects, symptom scores, and quality of life. RESULTS: Forty-three participants (52%) received azithromycin and 40 (48%) received placebo and were included in the modified intention-to-treat analysis. At end of study, the median number of exacerbations in the azithromycin group was 0 (interquartile range [IQR], 0-1), compared with 2 (IQR, 1-3) in the placebo group (P < .001). Thirty-two (80%) placebo-treated vs 20 (46%) azithromycin-treated individuals had at least 1 exacerbation (hazard ratio, 0.29 [95% CI, 0.16-0.51]). In a mixed-model analysis, change in forced expiratory volume in the first second of expiration (percent of predicted) over time differed between groups (F1,78.8 = 4.085, P = .047), with an increase of 1.03% per 3 months in the azithromycin group and a decrease of 0.10% per 3 months in the placebo group. Gastrointestinal adverse effects occurred in 40% of patients in the azithromycin group and in 5% in the placebo group (relative risk, 7.44 [95% CI, 0.97-56.88] for abdominal pain and 8.36 [95% CI, 1.10-63.15] for diarrhea) but without need for discontinuation of study treatment. A macrolide resistance rate of 88% was noted in azithromycin-treated individuals, compared with 26% in the placebo group. CONCLUSIONS AND RELEVANCE: Among adults with non-CF bronchiectasis, the daily use of azithromycin for 12 months compared with placebo resulted in a lower rate of infectious exacerbations. This could result in better quality of life and might influence survival, although effects on antibiotic resistance need to be considered. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00415350.
|
Authors | Josje Altenburg, Casper S de Graaff, Ymkje Stienstra, Jacobus H Sloos, Eric H J van Haren, Ralph J H Koppers, Tjip S van der Werf, Wim G Boersma |
Journal | JAMA
(JAMA)
Vol. 309
Issue 12
Pg. 1251-9
(Mar 27 2013)
ISSN: 1538-3598 [Electronic] United States |
PMID | 23532241
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Biomarkers
- Azithromycin
|
Topics |
- Adult
- Aged
- Anti-Bacterial Agents
(adverse effects, therapeutic use)
- Azithromycin
(adverse effects, therapeutic use)
- Bacterial Infections
(etiology, prevention & control)
- Biomarkers
(blood)
- Bronchiectasis
(complications)
- Double-Blind Method
- Drug Resistance, Bacterial
- Female
- Humans
- Inflammation
- Lung
(physiopathology)
- Male
- Middle Aged
- Quality of Life
- Respiratory Function Tests
- Respiratory Tract Infections
(etiology, prevention & control)
- Sputum
(microbiology)
|